JP2013507423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507423A5 JP2013507423A5 JP2012533614A JP2012533614A JP2013507423A5 JP 2013507423 A5 JP2013507423 A5 JP 2013507423A5 JP 2012533614 A JP2012533614 A JP 2012533614A JP 2012533614 A JP2012533614 A JP 2012533614A JP 2013507423 A5 JP2013507423 A5 JP 2013507423A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- alkylene
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 239000011780 sodium chloride Substances 0.000 claims 15
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 Oc1c2ncccc2c(*CCC**CCCCc2c(CN3)ccc(F)c2)nc1C3=O Chemical compound Oc1c2ncccc2c(*CCC**CCCCc2c(CN3)ccc(F)c2)nc1C3=O 0.000 description 6
- DKHHQXQSYABQJL-UHFFFAOYSA-N Oc1c2ncccc2c(N(CC2)CCN2C(CCCCOc2c(CN3)ccc(F)c2)=O)nc1C3=O Chemical compound Oc1c2ncccc2c(N(CC2)CCN2C(CCCCOc2c(CN3)ccc(F)c2)=O)nc1C3=O DKHHQXQSYABQJL-UHFFFAOYSA-N 0.000 description 2
- DJSWACRSJDFNCN-UHFFFAOYSA-N CN(c(c1c2nccc1)nc(C(NCc(ccc(F)c1)c1OCCCC1)=O)c2O)S1(=O)=O Chemical compound CN(c(c1c2nccc1)nc(C(NCc(ccc(F)c1)c1OCCCC1)=O)c2O)S1(=O)=O DJSWACRSJDFNCN-UHFFFAOYSA-N 0.000 description 1
- LKLWVPSCSCVWGP-UHFFFAOYSA-N CN(c(c1cccnc11)nc(C(NCc(ccc(F)c2)c2C(NCCCCC2)=O)=O)c1O)S2(=O)=O Chemical compound CN(c(c1cccnc11)nc(C(NCc(ccc(F)c2)c2C(NCCCCC2)=O)=O)c1O)S2(=O)=O LKLWVPSCSCVWGP-UHFFFAOYSA-N 0.000 description 1
- RBKVDOCDQFUZNY-UHFFFAOYSA-N CN(c(nc1C(NCc(c(C(N2)=O)c3)ccc3F)=O)c(cccn3)c3c1O)S2(C=O)=O Chemical compound CN(c(nc1C(NCc(c(C(N2)=O)c3)ccc3F)=O)c(cccn3)c3c1O)S2(C=O)=O RBKVDOCDQFUZNY-UHFFFAOYSA-N 0.000 description 1
- HBCBKKAPEYFKAY-UHFFFAOYSA-N CN(c(nc1C(NCc(ccc(F)c2)c2C(N2)=O)=O)c(cccn3)c3c1O)S2(=O)=O Chemical compound CN(c(nc1C(NCc(ccc(F)c2)c2C(N2)=O)=O)c(cccn3)c3c1O)S2(=O)=O HBCBKKAPEYFKAY-UHFFFAOYSA-N 0.000 description 1
- WFLLTQMZWWKFPJ-UHFFFAOYSA-N CN(c(nc1C(NCc(ccc(F)c2)c2O2)=O)c(cccn3)c3c1O)S2(=O)=O Chemical compound CN(c(nc1C(NCc(ccc(F)c2)c2O2)=O)c(cccn3)c3c1O)S2(=O)=O WFLLTQMZWWKFPJ-UHFFFAOYSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- XDCXCOVMWVMQKD-UHFFFAOYSA-N CNc(c1c2nccc1)nc(C(NCc(ccc(F)c1)c1OCCCCS=O)=O)c2O Chemical compound CNc(c1c2nccc1)nc(C(NCc(ccc(F)c1)c1OCCCCS=O)=O)c2O XDCXCOVMWVMQKD-UHFFFAOYSA-N 0.000 description 1
- XCRGEIYGLIHOEN-UHFFFAOYSA-O Oc1c2[nH+]cccc2c(N(CC2)CCN2CCCNC(c2c(CN3)ccc(F)c2)=O)nc1C3=O Chemical compound Oc1c2[nH+]cccc2c(N(CC2)CCN2CCCNC(c2c(CN3)ccc(F)c2)=O)nc1C3=O XCRGEIYGLIHOEN-UHFFFAOYSA-O 0.000 description 1
- ZQBYIJLPVNOCCD-UHFFFAOYSA-N Oc1c2ncccc2c(N(CC2)CCN2CCCCNC(c2c(CN3)ccc(F)c2)=O)nc1C3=O Chemical compound Oc1c2ncccc2c(N(CC2)CCN2CCCCNC(c2c(CN3)ccc(F)c2)=O)nc1C3=O ZQBYIJLPVNOCCD-UHFFFAOYSA-N 0.000 description 1
- XCRGEIYGLIHOEN-UHFFFAOYSA-N Oc1c2ncccc2c(N(CC2)CCN2CCCNC(c2c(CN3)ccc(F)c2)=O)nc1C3=O Chemical compound Oc1c2ncccc2c(N(CC2)CCN2CCCNC(c2c(CN3)ccc(F)c2)=O)nc1C3=O XCRGEIYGLIHOEN-UHFFFAOYSA-N 0.000 description 1
- JOEMIFWIDNWIPI-UHFFFAOYSA-N Oc1c2ncccc2c(NCCCCCCCNC(c2cc(F)ccc2CN2)=O)nc1C2=O Chemical compound Oc1c2ncccc2c(NCCCCCCCNC(c2cc(F)ccc2CN2)=O)nc1C2=O JOEMIFWIDNWIPI-UHFFFAOYSA-N 0.000 description 1
- HDKRKGLHVPLWBB-UHFFFAOYSA-N Oc1c2ncccc2c(NCCCCNC(c2cc(F)ccc2CN2)=O)nc1C2=O Chemical compound Oc1c2ncccc2c(NCCCCNC(c2cc(F)ccc2CN2)=O)nc1C2=O HDKRKGLHVPLWBB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172853.5 | 2009-10-13 | ||
| EP09172853 | 2009-10-13 | ||
| PCT/EP2010/065300 WO2011045330A1 (en) | 2009-10-13 | 2010-10-13 | Macrocyclic integrase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507423A JP2013507423A (ja) | 2013-03-04 |
| JP2013507423A5 true JP2013507423A5 (de) | 2013-11-21 |
| JP5624148B2 JP5624148B2 (ja) | 2014-11-12 |
Family
ID=41720665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533614A Active JP5624148B2 (ja) | 2009-10-13 | 2010-10-13 | 大環状インテグラーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8497270B2 (de) |
| EP (1) | EP2488521B1 (de) |
| JP (1) | JP5624148B2 (de) |
| KR (1) | KR20120087916A (de) |
| CN (1) | CN102574854B (de) |
| AU (1) | AU2010305805B2 (de) |
| BR (1) | BR112012008586A2 (de) |
| CA (1) | CA2777664C (de) |
| EA (1) | EA019558B1 (de) |
| ES (1) | ES2446720T3 (de) |
| IL (1) | IL218845A0 (de) |
| MX (1) | MX2012004426A (de) |
| NZ (1) | NZ598766A (de) |
| WO (1) | WO2011045330A1 (de) |
| ZA (1) | ZA201202516B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2487176A1 (de) * | 2011-02-14 | 2012-08-15 | Elanco Animal Health Ireland Limited | Makrozyklische Integrasehemmer zur Verwendung bei der Behandlung von felinem Immundefizienz-Virus |
| WO2014008636A1 (en) * | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| EP2931730B1 (de) | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazinderivate als hiv-integrase-hemmer |
| WO2014172188A2 (en) | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| WO2014183532A1 (en) | 2013-05-17 | 2014-11-20 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| WO2014200880A1 (en) | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| PE20160501A1 (es) | 2013-09-27 | 2016-05-14 | Merck Sharp & Dohme | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| BR112018001065A2 (pt) | 2015-07-21 | 2018-09-11 | Tp Therapeutics, Inc. | macrociclos diarila quirais e usos dos mesmos |
| WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| CN110062627A (zh) | 2016-12-02 | 2019-07-26 | 默沙东公司 | 可用作hiv整合酶抑制剂的三环杂环化合物 |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| EP3573984A4 (de) | 2017-01-26 | 2020-07-29 | Merck Sharp & Dohme Corp. | Als hiv-integrase-inhibitoren nützliche, substituierte chinolizinderivate |
| BR112020001695A2 (pt) | 2017-07-28 | 2020-07-21 | Turning Point Therapeutics, Inc. | compostos macrocíclicos e usos dos mesmos |
| ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
| KR20210142711A (ko) | 2019-03-22 | 2021-11-25 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
| CN112358477A (zh) * | 2020-11-10 | 2021-02-12 | 牡丹江医学院 | 一种用于治疗胆囊炎的药物及其制备方法 |
| SI4196479T1 (sl) | 2021-01-19 | 2024-01-31 | Gilead Sciences, Inc. | Substituirane piridotriazinske spojine in njihove uporabe |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS210880B1 (cs) | 1979-10-19 | 1982-01-29 | Jiri Krepelka | Substituované imidy kyselin 4-arylnaftalen-2,3-dikarboxylových |
| CS225002B1 (cs) | 1980-12-12 | 1984-02-13 | Krepelka Jiri | Deriváty 9-fenyl-1H-benzo/f/isoindol-1,3-dionu a způsob jejich výroby |
| JPH04217684A (ja) | 1990-05-30 | 1992-08-07 | Shionogi & Co Ltd | アルド−ス還元酵素阻害物質 |
| US5760065A (en) * | 1994-09-13 | 1998-06-02 | Kyowa Hakko Kogyo Co., Ltd. | Anti-HIV agent |
| US20050010048A1 (en) | 2000-10-12 | 2005-01-13 | Linghang Zhuang | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
| ATE364385T1 (de) | 2000-10-12 | 2007-07-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| IL155089A0 (en) | 2000-10-12 | 2003-10-31 | Merck & Co Inc | Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| EP1326610B1 (de) | 2000-10-12 | 2006-11-15 | Merck & Co., Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| US20040157804A1 (en) | 2002-10-16 | 2004-08-12 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| SK2662004A3 (sk) | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
| BR0317749A (pt) | 2002-12-27 | 2005-11-22 | Angeletti P Ist Richerche Bio | Composto, composição farmacêutica, e, uso de um composto |
| US6890942B2 (en) | 2003-05-16 | 2005-05-10 | Bristol-Myers Squibb Company | Acyl sulfonamides as inhibitors of HIV integrase |
| ATE433974T1 (de) | 2003-09-19 | 2009-07-15 | Gilead Sciences Inc | Azachinolinolphosphonatverbindungen als integraseinhibitoren |
| EP1725554A1 (de) | 2004-03-09 | 2006-11-29 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv-integrasehemmer |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| DK3187225T3 (da) | 2005-04-28 | 2022-02-28 | Viiv Healthcare Co | Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet |
| WO2007019098A2 (en) * | 2005-08-04 | 2007-02-15 | Smithkline Beecham Corporation | Hiv integrase inhibitors |
| MX2008005137A (es) * | 2005-10-27 | 2008-09-29 | Shionogi & Co | Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa. |
| US8039458B2 (en) * | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| CA2716079C (en) * | 2008-03-10 | 2018-01-16 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
-
2010
- 2010-10-13 CN CN201080046163.3A patent/CN102574854B/zh active Active
- 2010-10-13 NZ NZ598766A patent/NZ598766A/xx not_active IP Right Cessation
- 2010-10-13 ES ES10772998.0T patent/ES2446720T3/es active Active
- 2010-10-13 EA EA201270540A patent/EA019558B1/ru not_active IP Right Cessation
- 2010-10-13 BR BR112012008586A patent/BR112012008586A2/pt not_active IP Right Cessation
- 2010-10-13 US US13/395,891 patent/US8497270B2/en active Active
- 2010-10-13 WO PCT/EP2010/065300 patent/WO2011045330A1/en active Application Filing
- 2010-10-13 MX MX2012004426A patent/MX2012004426A/es active IP Right Grant
- 2010-10-13 JP JP2012533614A patent/JP5624148B2/ja active Active
- 2010-10-13 EP EP10772998.0A patent/EP2488521B1/de active Active
- 2010-10-13 CA CA2777664A patent/CA2777664C/en active Active
- 2010-10-13 KR KR1020127009345A patent/KR20120087916A/ko active IP Right Grant
- 2010-10-13 AU AU2010305805A patent/AU2010305805B2/en active Active
-
2012
- 2012-03-26 IL IL218845A patent/IL218845A0/en unknown
- 2012-04-05 ZA ZA2012/02516A patent/ZA201202516B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507423A5 (de) | ||
| JP2011518833A5 (de) | ||
| JP2010536766A5 (de) | ||
| JP2013518107A5 (de) | ||
| JP2009535462A5 (de) | ||
| JP2012502037A5 (de) | ||
| JP2013512277A5 (de) | ||
| JP2013540713A5 (de) | ||
| JP2009535358A5 (de) | ||
| JP2012512863A5 (de) | ||
| JP2013032389A5 (de) | ||
| JP2013542247A5 (de) | ||
| JP2012092103A5 (de) | ||
| JP2009526034A5 (de) | ||
| JP2010077141A5 (de) | ||
| JP2014500861A5 (de) | ||
| JP2007302689A5 (de) | ||
| JP2011527299A5 (de) | ||
| JP2020097577A5 (de) | ||
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| JP2011520775A5 (de) | ||
| JP2012532883A5 (de) | ||
| JP2008542386A5 (de) | ||
| JP2009522364A5 (de) | ||
| JP2013513607A5 (de) |